Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
58 hedge funds and large institutions have $52.5M invested in Northwest Biotherapeutics, Inc. Common stock in 2014 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
124% more capital invested
Capital invested by funds: $23.5M → $52.5M (+$29M)
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
51% more call options, than puts
Call options by funds: $4.19M | Put options by funds: $2.78M
32% more funds holding
Funds holding: 44 → 58 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$2.03M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$1.19M |
| 3 |
Morgan Stanley
New York
|
+$1.07M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$835K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$796K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$2.07M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$903K |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$212K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$107K |
| 5 |
WC
Woodstock Corp
Boston,
Massachusetts
|
-$79.8K |
NWBO Hedge Fund Activity: Q1 2014 in Review
58 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2014, worth a combined $52.5M — up 124% from $23.5M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NWBO positions and 3 closed out — a net gain of 14 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was Franklin Resources, adding an estimated $2.03M. The largest seller was Whitebox Advisors, exiting entirely with an estimated $2.07M sold.
- 58 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2014, up from 44 in Q4 2013.
- Funds reported $52.5M of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2014, up 124% quarter-over-quarter.
- 17 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2014 and 3 closed out, a net change of +14 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2014 was Franklin Resources, an estimated $2.03M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2014 was Whitebox Advisors, an estimated $2.07M sold.
Based on aggregated 13F filings for Q1 2014.